Diligence memo · auto-generated · as of July 2, 2026
Aclipse Therapeutics LLC
Aclipse Therapeutics LLC looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Aclipse Therapeutics LLC operates in Pharmaceuticals, based in RADNOR.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aclipse Therapeutics LLC has raised $2.5M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.2M on 2018-01-31.
Most recent recorded round closed around 2020-08-05.
Valuation (modeled)modeled
Provath models Aclipse Therapeutics LLC at approximately $4.2M (range $87K–$32M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.07× the median modeled value of Seed Pharmaceuticals companies in 2019–2021 (49 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 5.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 31% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 7% of those peers.
Closest niche peers: Wiesman Capital & Co., LLC, Curzion Pharmaceuticals, Inc., Providence Therapeutics Inc., EnBiotix, Inc., Metuchen Pharmaceuticals, LLC.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.